Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Houshmandi, S. S.
Right arrow Articles by Gutmann, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houshmandi, S. S.
Right arrow Articles by Gutmann, D. H.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
NEUROLOGY 2006;67:1863-1866
© 2006 American Academy of Neurology
Brief Communications

Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor

S. S. Houshmandi, PhD, E. I. Surace, PhD, H. B. Zhang, MD, PhD, G. N. Fuller, MD, PhD and D. H. Gutmann, MD, PhD

From the Department of Neurology, Washington University School of Medicine, St. Louis, MO (S.S.H., E.I.S., H.B.Z., D.H.G.); and the Department of Pathology, MD Anderson Cancer Center, Houston, TX (G.N.F.).

Address correspondence and reprint requests to Dr. David H. Gutmann, Department of Neurology, Washington University School of Medicine, Box 8111; 660 S. Euclid Avenue, St. Louis, MO 63110; e-mail: gutmannd{at}wustl.edu

Tumor suppressor in lung cancer-1 (TSLC1) loss is common in many human cancers, including meningioma. In this study, we demonstrate that TSLC1 protein and RNA expression is lost in 60% to 65% of high-grade gliomas, and that TSLC1 reintroduction into glioma cells results in growth suppression. Moreover, Tslc1 loss in mice results in increased astrocyte proliferation in vivo and in vitro. These data indicate that TSLC1 functions as a glioma tumor suppressor.

Supported in part from grants from the James F. McDonnell Foundation and the Department of Defense (DAMD-17-04-0266 to D.H.G.). S.S.H. is supported by a nested postdoctoral fellowship from the Department of Defense. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842.

Disclosure: The authors report no conflicts of interest.

Received May 12, 2006. Accepted in final form July 28, 2006.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y.-K. I. Lau, L. B. Murray, S. S. Houshmandi, Y. Xu, D. H. Gutmann, and Q. Yu
Merlin Is a Potent Inhibitor of Glioma Growth
Cancer Res., July 15, 2008; 68(14): 5733 - 5742.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.